Refine by
Drug Eluting Coronary Stent Articles & Analysis
14 news found
He also spent three years on an expatriate assignment in Europe leading the launch of Medtronic’s first drug eluting coronary stent. Prior to Medtronic, he spent four years at ABN AMRO bank in Chicago focused on healthcare transactions. ...
The trial evaluated the safety and performance of the Company’s Fantom sirolimus-eluting bioresorbable coronary scaffold in over 240 patients outside the United States. ...
Arterius Limited, a Leeds-based, UK company developing innovative medical devices with a focus on next generation bioresorbable coronary and peripheral stents, has announced that it has appointed Steve Parker as Chief Executive Officer. ...
The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology, allowing for the restoration of normal vessel functions essential to cardiovascular performance. ...
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced financial and operating results as of and for the second quarter ended June 30, 2021. Second Quarter 2021 and recent highlights Revenue of $1,038,000 an increase of 231.6% compared to the same ...
The BIOADAPTOR RCT is evaluating the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. ...
Braun Group of Companies and Japan-based Nipro Corporation to advance coronary artery disease management. The companies are ideally positioned to leverage shared resources to accelerate the initiation of the U.S. clinical trial of the SeQuent Please ReX to study the treatment of coronary in-stent restenosis (ISR), which is defined as the gradual ...
The DynamX Bioadaptor is a metal implant with a drug-eluting bioresorbable polymer coating that supports the coronary artery during healing, with radial strength similar to DES. ...
– January 27, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. ...
International Trial to Compare Bioadaptor, a Novel Coronary Artery Implant Designed to Adapt to Vessel Physiology, with Traditional Drug Eluting Stents International Trial to Compare Bioadaptor, a MILPITAS, Calif. ...
Anderson was a key architect behind the launch of the world’s first drug-eluting stent, the CYPHER® Sirolimus-eluting Coronary Stent. ...
A prospective, multi-center, single-arm, open-label post marketing clinical trial, to assess the safety and efficacy of the EluNIR Drug Eluting Stent (DES) in combination with shortened DAPT duration, in patients undergoing PCI who are considered to be at high bleeding risk. ...
ByMedinol
The oral presentations will feature the Virtue® Sirolimus-Eluting Balloon which has Breakthrough Device Designation from the U.S Food and Drug Administration for the treatment of below-the-knee disease and coronary in-stent restenosis, for which the Company has a global strategic partnership with Terumo Corporation. ...
No stent fractures were reported in either treatment group. The 24-month results now released confirm this positive trend and suggest a tangible advantage for the 3D helical stent over current market-leading stents. ...